%0 Journal Article
%A Mackay, Alan
%A Burford, Anna
%A Molinari, Valeria
%A Jones, David
%A Izquierdo, Elisa
%A Brouwer-Visser, Jurriaan
%A Giangaspero, Felice
%A Haberler, Christine
%A Pietsch, Torsten
%A Jacques, Thomas S
%A Figarella-Branger, Dominique
%A Rodriguez, Daniel
%A Morgan, Paul S
%A Raman, Pichai
%A Waanders, Angela J
%A Resnick, Adam C
%A Massimino, Maura
%A Garrè, Maria Luisa
%A Smith, Helen
%A Capper, David
%A Pfister, Stefan
%A Würdinger, Thomas
%A Tam, Rachel
%A Garcia, Josep
%A Thakur, Meghna Das
%A Vassal, Gilles
%A Grill, Jacques
%A Jaspan, Tim
%A Varlet, Pascale
%A Jones, Chris
%T Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
%J Cancer cell
%V 33
%N 5
%@ 1535-6108
%C Cambridge, Mass.
%I Cell Press
%M DKFZ-2018-00623
%P 829 - 842.e5
%D 2018
%X The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term 'HGG' in the pediatric population.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29763623
%2 pmc:PMC5956280
%R 10.1016/j.ccell.2018.04.004
%U https://inrepo02.dkfz.de/record/134833